Cryoport Reports Second Quarter 2026 Financial Results
- Cryoport reported Q2 2026 total revenue of $49.0 million, an 8% year-over-year increase.
- Life Sciences Services revenue grew 15% year-over-year to $27.969 million.
- BioStorage/BioServices revenue increased 25% year-over-year to $5.610 million.
- Life Sciences Products revenue remained flat at $21.002 million, down 0% year-over-year.
- The company supported 779 global clinical trials & 22 commercially approved cell & gene therapies as of June 30, 2026.
- Revenue from supporting commercial cell & gene therapies rose 9% year-over-year to $9.4 million.
- Revenue from supporting CGT clinical trials grew 12% year-over-year to $13.4 million.
- Cryoport achieved positive adjusted EBITDA of $0.4 million in Q2 2026, a significant milestone.
- Total gross margin for Q2 2026 was 46.6%, down slightly from 47.0% in Q2 2025.
- Net loss attributable to common stockholders was $10.3 million, or $0.20 per share, for Q2 2026.
- Four customers filed Biologics License Applications or Marketing Authorization Applications during Q2 2026.
- Customer Orca Bio received FDA approval for TREGZI™, while Vertex Pharmaceuticals received supplemental approval for CASGEVY®.
- The company anticipates 11 possible BLA/MAA applications, five new therapy approvals, and one label expansion for the remainder of 2026.
- Operational milestones included the selection of IntegriCell® services by Verismo Therapeutics & shipments of HE freezers from the Chengdu facility.
- BioServices operations at the Paris Global Supply Chain Center are scheduled for launch in Q4 2026.
- The Santa Ana, California Global Supply Chain Center is expected to launch in Q4 2026.
- Cash, cash equivalents, & short-term investments totaled $396.7 million as of June 30, 2026.